← Leaderboards
John E Gerich
University Of Rochester
$2,977,172
Attributed
$2,977,172
Total exposure
19
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $541.9K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$2,977,172 · 19
By mechanism
R01$2,702,241 · 1
M01$274,931 · 18
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Arnold William Tank$3,123,086
- Thomas K Graves$153,279
- Laurence S Jacobs$83,599
- David John Culp$4,486,180
- Nicholas Jospe$54,491
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchNoninsulin Dependent Diabetes MellitusHuman Therapy EvaluationDiabetes Mellitus TherapyInsulinHypoglycemic AgentsGlucose MetabolismDrug Screening /EvaluationGluconeogenesisInsulin Dependent Diabetes MellitusKidney FunctionPharmacokineticsHypoglycemiaInhalation Drug AdministrationGlucagonCombination ChemotherapyHormone Regulation /Control MechanismLiver MetabolismGlucose Clamp TechniqueInsulin Sensitivity /ResistanceFastingKidneyDrug Administration Rate /Duration
Grant awards (38)
Alpha and Beta Cell Function in Normal and Diabetic Man$537,960
R01 · FY2007 · DK · contact PI
Alpha and Beta Cell Function in Normal and Diabetic Man$539,828
R01 · FY2006 · DK · contact PI
Alpha and Beta Cell Function in Normal and Diabetic Man$538,710
R01 · FY2005 · DK
HORMONAL AND SUBSTRATE REGULATION OF RENAL AND HEPATIC GLUCONEOGENESIS$2,915
M01 · FY2005 · RR
MECHANISM FOR IMPAIRED GLUCAGON RESPONSE TO HYPOGLYCEMIA IN DM$265
M01 · FY2005 · RR
Alpha and Beta Cell Function in Normal and Diabetic Man$524,511
R01 · FY2004 · DK
Comparison of the Effects of Glyburide and Glimpiride$85,419
M01 · FY2004 · RR
Glucose Metabolism During a Meal$9,016
M01 · FY2004 · RR
Mechanism for Impaired Glucagon Response to Hypoglycemia in DM$474
M01 · FY2004 · RR
Alpha and Beta Cell Function in Normal and Diabetic Man$509,235
R01 · FY2003 · DK
ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN$51,997
R01 · FY2002 · DK
BRL49653C-- STUDY OF ABSORPTIVE, POST ABS SLELETAL MUSCLE/HEPATIC METABOLISM$0
M01 · FY2002 · RR
ROLE OF THE KIDNEY IN GLUCOSE HOMEOSTASIS IN NORMAL AND DIABETIC HUMANS$0
M01 · FY2002 · RR
HUMAN KIDNEY IN GLUCONEOGENESIS AND PROTEIN METABOLISM$0
M01 · FY2002 · RR
GLUCAGON RECEPTOR ANTAGONIST BAY 27-9955 IN NIDDM$0
M01 · FY2002 · RR
INHALED VS SUBCUTANEOUS HUMAN INSULIN IN IDDM$0
M01 · FY2002 · RR
INHALED VS SUBCUTANEOUS HUMAN INSULIN IN NIDDM$0
M01 · FY2002 · RR
INHALED HUMAN INSULIN IN SUBJECTS WITH TYPE II DIABETES MELLITUS$0
M01 · FY2002 · RR
SINGLE ORAL DOSES OF SDZ DJN 608 IN NIDDM$0
M01 · FY2002 · RR
HYPOLIPIDEMIC THERAPY WITH ATORVASTATIN IN NIDDM$0
M01 · FY2002 · RR
STUDY OF BTS 67 582 IN PATIENTS WITH NIDDM ON DIET THERAPY$19,613
M01 · FY2001 · RR
ROLE OF THE KIDNEY IN GLUCOSE HOMEOSTASIS IN NORMAL AND DIABETIC HUMANS$19,613
M01 · FY2001 · RR
EFFECT OF GLYCEMIC CONTROL AND MODE OF TREATMENT IN HYPOGLYCEMIA UNAWARENESS$19,613
M01 · FY2001 · RR
PIMAGEDINE IN PATIENTS WITH TYPE 2 OVERT DIABETIC NEPHROPATHY$19,613
M01 · FY2001 · RR
ESTIMATION OF GLUCONEOGENESIS IN DIABETIC AND NORMAL POSTOPERATIVE HUMANS$19,613
M01 · FY2001 · RR
BRL49653C-- STUDY OF ABSORPTIVE, POST ABS SLELETAL MUSCLE/HEPATIC METABOLISM$19,613
M01 · FY2001 · RR
HOE 901 INSULIN W/ NPH INSULIN IN TYPE II DM PTS$14,791
M01 · FY2000 · RR
ROLE OF THE KIDNEY IN GLUCOSE HOMEOSTASIS IN NORMAL AND DIABETIC HUMANS$14,791
M01 · FY2000 · RR
ESTIMATION OF GLUCONEOGENESIS IN DIABETIC AND NORMAL POSTOPERATIVE HUMANS$14,791
M01 · FY2000 · RR
PIMAGEDINE IN PATIENTS WITH TYPE 2 OVERT DIABETIC NEPHROPATHY$14,791
M01 · FY2000 · RR
INHALED HUMAN INSULIN IN SUBJECTS WITH TYPE II DIABETES MELLITUS$0
M01 · FY2000 · RR
GLUCAGON RECEPTOR ANTAGONIST BAY 27-9955 IN NIDDM$0
M01 · FY2000 · RR
HUMAN KIDNEY IN GLUCONEOGENESIS AND PROTEIN METABOLISM$0
M01 · FY2000 · RR
BRL49653C-- STUDY OF ABSORPTIVE, POST ABS SLELETAL MUSCLE/HEPATIC METABOLISM$0
M01 · FY2000 · RR
HYPOLIPIDEMIC THERAPY WITH ATORVASTATIN IN NIDDM$0
M01 · FY2000 · RR
SINGLE ORAL DOSES OF SDZ DJN 608 IN NIDDM$0
M01 · FY2000 · RR
INHALED VS SUBCUTANEOUS HUMAN INSULIN IN IDDM$0
M01 · FY2000 · RR
INHALED VS SUBCUTANEOUS HUMAN INSULIN IN NIDDM$0
M01 · FY2000 · RR